CEO employed since 2014, born 1963. Holdings: 120 648 shares and 575 000 options
Göran Forsberg has a PhD in biochemistry and is associate professor and author of over 40 scientific publications. For over 30 years he has had leading positions in research and development, business development and investor relations at pharmaceutical and biotechnology companies, including KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. Forsberg has extensive experience in leading drug development and clinical trials, with a special focus on oncology. Forsberg is a board member of Guard Therapeutics International AB (publ).
COO employed since 2014, born 1963. Holdings: 31 600 shares and 205 000 options
Liselotte Larsson has a PhD in biotechnology and has over 20 years of experience in various management positions in pharmaceutical and biotechnology companies including BioGaia Fermentation, Novozymes Biopharma and Camurus. Larsson's main fields of expertise are business development, marketing & sales/out licensing, ISO certification, good manufacturing practice (GMP) and overall project management.
VP Clinical Development employed since 2015, born 1961. Holdings: 75 622 shares and 205 000 options
Lars Thorsson graduated with a PhD in clinical pharmacology in 1998 and has extensive experience from the pharmaceutical industry, including leading roles in clinical studies and project management in a large number of development phases at AstraZeneca and Novo Nordisk A/S. Thorsson has been responsible for evaluation and documentation of new substances and has the experience of regulatory activities and interactions with health authorities.
VP Research employed since 2015, born 1969. Holdings: 11 200 shares and 205 000 options
David Liberg graduated with a PhD in 2001 and has over twenty years of research experience within immunology and tumour biology. Liberg has worked within the pharmaceutical industry for the last fifteen years, with responsibility for early research projects and activities in tumour immunology. He has extensive experience of pre-clinical phase cancer projects. His most recent position was at Active Biotech AB, where he worked as Project Manager Drug Development as well as Head of Cell Biology and Biochemistry. Liberg has also carried out research at Imperial College in the UK and at Lund University.
CFO employed since 2017, born 1960. Holdings: 104 000 shares and 205 000 options
Bengt Jöndell has a BSc in Business Administration and a MSc in Chemical Engineering. Jöndell has extensive experience in various executive financial functions such as CFO and Chief Executive Officer at BTJ Group AB, Senior Financial Advisor for BoneSupport, CFO/Administrative Manager at Inpac, Business Controller at Pharmacia & Upjohn Consumer Healthcare, Pharmacia, Pharmacia Consumer Pharma and Pharmacia Nicorette. Jöndell’s most recent position was CFO for Enzymatica AB.
Peter Juul Madsen
VP CMC employed since 2020, born 1969. Holdings: 4100 shares and 205 000 options
Peter Juul Madsen has an MSc in Chemical Engineering from the Technical University of Denmark. He has over 20 years of experience in managing CMC development including process & analytical development and manufacturing of biological products. Madsen was most recently CMC Project Director at Lundbeck and has extensive experience from outsourcing to contract manufacturing organizations from different CMC project managing positions in e.g. Lundbeck, Genmab and Zealand Pharma.
VP Regulatory Affairs employed since 2020, born 1968. Holdings: 2 300 shares and 205 000 options
Susanne Lagerlund has an MSc in Chemical Engineering and has over 25 years of experience from the pharmaceutical industry in leading positions at LEO Pharma and AstraZeneca, mainly within Regulatory Affairs. Lagerlund’s most recent role was as Director, Established Portfolio Management at LEO Pharma, where she had responsibility for strategic and tactical management of commercialized portfolios. Lagerlund has also during the last couple of years been responsible within LEO Pharma R&D for the integration of a number of acquired dermatology projects into the commercial portfolio.
VP Biometrics employed since 2021, born 1969.Holdings: 0 shares and 100 000 options
Nedjad Losic holds an MSc in Mathematics and a diploma in Management of Medical Product Innovation (SIMI). Losic has over 25 years of experience in providing biostatistics expertise in clinical drug development, mostly in antibody development and oncology. Losic has been directly involved in the planning and obtaining market approvals for several biological drugs at Genmab and Y-mAbs Therapeutics. Losic has held managerial positions for Ferring, Spadille and Genmab and most recently, as Senior Project Biostatistician in Y-mAbs.
CMO employed since 2022, born 1966. Holdings: 1 870 shares
Roger Belusa has an MD (1996) and a PhD (2001) from Karolinska Institute with a focus on oncology and clinical pharmacology. Belusa has previously held the position as CMO and has also worked in the biotech/pharma industry during the last twenty years in different positions within pharmacovigilance, clinical operations, competitive intelligence, and medical affairs for companies such as BioSeeker, Avaris, Nanologica, Ipsen and Pfizer. Belusa serves as a member of the Board of Directors for Doctors of the World Sweden.